De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Lupin Toekomstige groei
Future criteriumcontroles 2/6
Lupin is forecast to grow earnings and revenue by 18.7% and 8.9% per annum respectively. EPS is expected to grow by 18.5% per annum. Return on equity is forecast to be 18.6% in 3 years.
Belangrijke informatie
18.7%
Groei van de winst
18.5%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 18.1% |
Inkomstengroei | 8.9% |
Toekomstig rendement op eigen vermogen | 18.6% |
Dekking van analisten | Good |
Laatst bijgewerkt | 26 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2027 | 262,596 | 37,156 | 35,628 | N/A | 21 |
3/31/2026 | 247,467 | 35,011 | 30,049 | N/A | 34 |
3/31/2025 | 221,259 | 27,612 | 20,612 | N/A | 34 |
6/30/2024 | 207,971 | 22,635 | N/A | N/A | N/A |
3/31/2024 | 200,108 | 19,145 | 27,195 | 36,484 | N/A |
12/31/2023 | 194,801 | 17,910 | N/A | N/A | N/A |
9/30/2023 | 186,049 | 13,314 | 18,582 | 34,087 | N/A |
6/30/2023 | 177,119 | 9,714 | N/A | N/A | N/A |
3/31/2023 | 166,417 | 4,301 | 3,976 | 18,972 | N/A |
12/31/2022 | 160,946 | -3,239 | N/A | N/A | N/A |
9/30/2022 | 159,333 | 682 | -19,299 | -9,456 | N/A |
6/30/2022 | 158,791 | -21,596 | N/A | N/A | N/A |
3/31/2022 | 164,055 | -15,280 | -5,378 | 3,673 | N/A |
12/31/2021 | 163,052 | -5,497 | N/A | N/A | N/A |
9/30/2021 | 161,616 | -6,570 | 22,007 | 29,207 | N/A |
6/30/2021 | 159,053 | 16,521 | N/A | N/A | N/A |
3/31/2021 | 151,630 | 12,165 | 11,441 | 18,218 | N/A |
12/31/2020 | 152,260 | 11,458 | N/A | N/A | N/A |
9/30/2020 | 149,777 | -1,609 | -4,671 | 523 | N/A |
6/30/2020 | 150,249 | -5,572 | N/A | N/A | N/A |
3/31/2020 | 153,748 | -3,995 | 7,957 | 14,688 | N/A |
12/31/2019 | 174,693 | -4,428 | N/A | N/A | N/A |
9/30/2019 | 176,892 | 3,138 | 21,219 | 29,124 | N/A |
6/30/2019 | 172,806 | 7,068 | N/A | N/A | N/A |
3/31/2019 | 146,646 | 5,121 | 6,806 | 16,660 | N/A |
12/31/2018 | 163,114 | -4,665 | N/A | N/A | N/A |
9/30/2018 | 157,822 | -931 | N/A | N/A | N/A |
6/30/2018 | 157,829 | 960 | N/A | N/A | N/A |
3/31/2018 | 157,765 | 2,513 | N/A | 17,512 | N/A |
12/31/2017 | 159,233 | 14,150 | N/A | N/A | N/A |
9/30/2017 | 164,306 | 18,264 | N/A | N/A | N/A |
6/30/2017 | 167,693 | 20,336 | N/A | N/A | N/A |
3/31/2017 | 173,674 | 25,575 | N/A | 41,135 | N/A |
12/31/2016 | 173,910 | 29,351 | N/A | N/A | N/A |
9/30/2016 | 164,558 | 28,265 | N/A | N/A | N/A |
6/30/2016 | 154,918 | 25,841 | N/A | N/A | N/A |
3/31/2016 | 141,316 | 22,607 | N/A | -3,824 | N/A |
12/31/2015 | 131,055 | 20,106 | N/A | N/A | N/A |
9/30/2015 | 127,273 | 20,823 | N/A | N/A | N/A |
6/30/2015 | 125,794 | 23,035 | N/A | N/A | N/A |
3/31/2015 | 127,700 | 24,032 | N/A | 27,331 | N/A |
12/31/2014 | 128,124 | 24,092 | N/A | N/A | N/A |
9/30/2014 | 126,567 | 22,839 | N/A | N/A | N/A |
6/30/2014 | 121,512 | 20,601 | N/A | N/A | N/A |
3/31/2014 | 112,866 | 18,364 | N/A | 20,039 | N/A |
12/31/2013 | 107,519 | 16,915 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 500257's forecast earnings growth (18.7% per year) is above the savings rate (6.7%).
Winst versus markt: 500257's earnings (18.7% per year) are forecast to grow faster than the Indian market (17.2% per year).
Hoge groeiwinsten: 500257's earnings are forecast to grow, but not significantly.
Omzet versus markt: 500257's revenue (8.9% per year) is forecast to grow slower than the Indian market (10.1% per year).
Hoge groei-inkomsten: 500257's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 500257's Return on Equity is forecast to be low in 3 years time (18.6%).